- Title
-
Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model
- Authors
- Beedie, S.L., Mahony, C., Walker, H.M., Chau, C.H., Figg, W.D., Vargesson, N.
- Source
- Full text @ Sci. Rep.
Anti-angiogenic anti-cancer drugs target intersomitic vessel outgrowth in fli1:EGFP embryos. Schematic of zebrafish embryo at 48 hpf. Black rectangular box indicates the imaging area used within this figure. (B) Treatment with 0.1% DMSO, (C) vandetanib (100 μg/mL), (D) sunitinib (100 μg/mL), (E) sorafenib (100 μg/mL), (F) axitinib (100 μg/mL), (G) pazopanib (100 μg/mL), (H) everolimus (100 μg/mL), (I) TNP-470 (100 μg/mL), and (J) CPS49 (10 μg/mL). (K) Vessel outgrowth and (L) number is reduced with anti-angiogenic treatment over a concentration gradient, with the exception of TNP-470 and vandetanib for vessel number. White arrow-heads show reduction in vessel outgrowth, white asterisks show complete loss of vessel. Scale bar = 100 μm. |